Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 Planned End Date changed from 30 Apr 2018 to 31 Oct 2019.
- 08 Jul 2014 New trial record